The Ozempic patient assistance program run by Novo Nordisk is the route designed for people who cannot pay for the medication at all: eligible low-income, uninsured US patients may receive their prescription at no cost. It is not the same thing as the copay savings card, and mixing the two up is one of the most common reasons people give up on Ozempic before they have worked through every option available to them.
This guide explains what the patient assistance program is, who it is built for, how it differs from the savings card, and what the realistic route map looks like if the pharmacy quotes you a price you cannot absorb. Criteria and prices in this space change often, so treat everything here as orientation rather than a quote, and verify current terms directly with the program and your prescriber.
What the Ozempic patient assistance program is
Novo Nordisk, the maker of Ozempic, operates a patient assistance program that provides medication at no cost to patients who meet its eligibility criteria. NovoCare is the umbrella name for the company's patient access and affordability resources, and the assistance program sits underneath it alongside other tools such as the copay savings card and a cash-pay option.
The purpose of a patient assistance program is narrow and specific. It exists for people who have no realistic way to pay: no prescription drug coverage, and a household income low enough that the retail price is simply out of reach. It is a charitable access channel, not a discount. If you are approved, the medication is supplied to you rather than sold to you at a reduced rate.
General eligibility themes
Program criteria are set by the manufacturer and are revised periodically, so the only reliable source is the program itself. That said, patient assistance programs in the US generally share a few recurring themes, and Novo Nordisk's is described in similar terms:
- US residency. Applicants are typically required to be residents of the United States.
- No prescription drug coverage. The program is generally aimed at patients who have no prescription coverage, or who cannot obtain it.
- Household income at or below a program threshold. There is an income ceiling. We are deliberately not quoting a dollar figure or a poverty-level percentage here, because those numbers move and the program's own current statement is the only version worth acting on.
- A completed application involving your prescriber. Patient assistance is not something you enrol in with a click. The application asks for documentation and usually requires the prescribing clinician to complete or sign part of it.
Nobody can promise you will qualify. Income thresholds exclude a large group of people who are genuinely squeezed but not low-income enough, and an application is a request, not an entitlement.
Patient assistance versus the copay savings card
This is the distinction that matters most, and it is worth being blunt about it. The two programs serve opposite populations.
The copay savings card is for patients who already have commercial or employer-sponsored insurance that covers Ozempic. It works by paying down part of the gap between your copay and a cap the manufacturer sets. It requires you to have insurance. The mechanics, the caps, and the reasons a card gets rejected at the counter are covered in detail in our guide to the Ozempic savings card.
The patient assistance program is, broadly, for the opposite situation: patients without prescription drug coverage whose income falls below the program threshold. Where the savings card reduces a copay, patient assistance replaces the purchase entirely for approved applicants.
Critically, manufacturer copay savings cards are generally not available to patients enrolled in government programs such as Medicare, Medicaid, or TRICARE. That exclusion is a legal one and it is close to universal across the industry. It creates the situation many readers find themselves in: on Medicare, told the savings card does not apply, and unsure what is left. Our guide to whether Medicare covers GLP-1 medications walks through that specific case.
The routes compared
The figures below are approximate US prices and change frequently. Verify each before relying on it.
| Route | Who it is for | Insurance status | What you pay | Main catch |
|---|---|---|---|---|
| Patient assistance program | Low-income patients who cannot afford the prescription | No prescription drug coverage | No cost if approved | Income ceiling, documentation, prescriber involvement, periodic renewal, and no guarantee of approval |
| Copay savings card | Patients whose plan already covers Ozempic | Commercial or employer insurance only | A reduced copay, up to a manufacturer cap | Generally barred for Medicare, Medicaid, and TRICARE; terms and caps change |
| NovoCare cash pay | Cash-paying patients who do not qualify for assistance | Any, including uninsured | About $499 per month (approximate) | Still a substantial ongoing cost, and it is a self-pay channel with its own conditions |
| Pharmacy discount cards | Uninsured patients shopping the cash price | Used instead of insurance | A modest discount off a list price of about $997 per month | Savings on a branded drug are usually small; cannot normally be combined with insurance |
For the wider picture across the whole drug class, see GLP-1 costs without insurance in 2026. For Ozempic specifically, the price without insurance breaks down the cash routes in more depth.
The diagnosis question that shapes everything
One fact sits underneath every coverage and assistance decision: Ozempic is FDA-approved for type 2 diabetes, not for weight loss. Prescribing it purely for weight is off-label, and insurers typically will not cover off-label use. That is why two people can be handed the same prescription and face completely different costs.
The same logic often shapes access programs. Coverage and assistance decisions frequently hinge on the documented diagnosis, so the reason written in your chart matters as much as your income. If your plan does cover the drug but is demanding a prior authorization first, the documented diagnosis is usually what moves the formulary decision. Ozempic itself, including its once-weekly dosing schedule of 0.25 mg for the first four weeks, then 0.5 mg, 1 mg, and a 2 mg maximum, is covered in our Ozempic overview.
How to apply for patient assistance
At a general level, the process looks like this. The specifics belong to the program, not to us.
- Step 1. Talk to your prescriber. Say plainly that cost is the barrier. Clinic staff deal with assistance applications routinely and often know which programs are currently open.
- Step 2. Gather your documentation. Expect to need proof of household income and proof of US residency, plus details of your insurance status or lack of it.
- Step 3. Have the clinician submit or co-sign. Patient assistance applications generally require the prescriber to complete a clinical section, confirm the prescription, and sign.
- Step 4. Verify current criteria with the program. Before you invest effort, confirm the income threshold, the required forms, and the renewal period directly with the program. Published thresholds change, and third-party summaries go stale quickly.
If patient assistance is not an option
Plenty of people fall into the gap: too much income for assistance, no commercial insurance for the savings card, or on Medicare and excluded from copay support. Realistic remaining routes include the NovoCare cash-pay option at roughly $499 per month, appealing or pursuing coverage through your plan if you have a qualifying diagnosis, and using pre-tax dollars where available. If you have a health account, FSA and HSA eligibility for GLP-1 medications is worth checking, since it effectively discounts the cost by your tax rate.
Compounded semaglutide is widely advertised from roughly $129 to $199 per month, but these are not FDA-approved products and quality depends entirely on the pharmacy that mixes them. If you are considering that route, read compounded GLP-1 sold online first and go in with your eyes open.
For scale: Ozempic's list price is about $997 per month and Wegovy, the weight-approved sibling molecule, lists at about $1,349. Semaglutide's weight-loss evidence base is strong, with the STEP 1 trial reporting a mean loss of roughly 15% of body weight over 68 weeks, which is why so many people are willing to fight this hard for access.3 That does not make the price payable, and there is no shame in asking a clinic for help finding a program.
This article is educational and is not medical or financial advice. Eligibility criteria, program terms, and prices change frequently, and no article can tell you whether you will qualify or what you will pay. Confirm current requirements directly with the Novo Nordisk patient assistance program and discuss your options with your prescriber and pharmacist before making decisions.
Scientific References
3 sources- 1
Novo Nordisk
NovoCare patient access and affordability resources
Novo Nordisk · 2026
- 2
U.S. Food and Drug Administration
Prescribing information
U.S. Food and Drug Administration · 2026
- 3
Wilding JPH, Batterham RL, Calanna S, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
New England Journal of Medicine · 384(11) · 2021PMID: 33567185
PubMed
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What is the Ozempic patient assistance program?
It is a Novo Nordisk program that provides Ozempic at no cost to eligible patients who cannot afford it. Eligibility generally involves US residency, having no prescription drug coverage, and household income at or below a program threshold. An application with prescriber involvement is required, and criteria change.
How do I get Ozempic for free?
The main legitimate route is the Novo Nordisk patient assistance program, which supplies medication at no cost to approved applicants. Ask your prescriber to help you apply, gather proof of income and US residency, and verify current eligibility criteria directly with the program. Approval is never guaranteed.
Who qualifies for Ozempic patient assistance?
Patient assistance is generally aimed at US residents who have no prescription drug coverage and whose household income falls at or below the program threshold. The prescriber usually completes part of the application. Because thresholds and rules are revised periodically, confirm the current criteria with the program itself.
Can Medicare patients use the Ozempic savings card?
Generally no. Manufacturer copay savings cards are typically unavailable to patients enrolled in government programs such as Medicare, Medicaid, or TRICARE. Medicare patients usually need other routes, including plan coverage where a qualifying diagnosis exists, cash-pay options, or separate assistance pathways worth asking about.
What is the difference between Ozempic patient assistance and the copay savings card?
Patient assistance supplies medication at no cost to low-income patients without prescription coverage. The copay savings card reduces the copay for patients who already have commercial or employer insurance covering Ozempic. They serve opposite populations, so the one you need depends on your insurance status.
Does the Ozempic patient assistance program cover weight loss?
Ozempic is FDA-approved for type 2 diabetes, not weight loss, and using it for weight alone is off-label. Coverage and assistance decisions frequently hinge on the documented diagnosis, so off-label weight use is typically not supported. Ask the program and your prescriber about your specific situation.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.